Effective today, Lone Carlbom has assumed the role of CEO of Bio-Works. Concurrently, the company’s CEO to date, Jonathan Royce, has resigned from his position in consultation with Bio-Works’ Board of Directors, effective immediately.

Lone Carlbom Assumes Role as CEO of Bio-Works

Effective today, Lone Carlbom has assumed the role of CEO of Bio-Works. Concurrently, the company’s CEO to date, Jonathan Royce, has resigned from his position in consultation with Bio-Works’ Board of Directors, effective immediately.

In line with the CEO transition, Bio-Works’ management team is intended to be reorganized with the following positions:

Arne Hauge, CFO and Head of Support Functions
Maria Åberg, Head of Production
Silvia Hellström, Head of Quality Assurance
Lone Carlbom will continue to oversee Product Management and R & D
A new Head of Sales will join the management team shortly.

“Under Jonathan Royce’s leadership, Bio-Works has seen significant development and initiatives. However, we have not achieved the results that both he and the Board anticipated”, said Peter Ehrenheim, Chairman of the Board at Bio-Works. “We agree that new leadership and a strategic reset are necessary to move Bio-Works forward and realize the potential of our technology platform. Initially, Lone Carlbom will focus entirely on the company’s operations. The Board will take a more active role in implementing the company’s commercial strategy and its communications with the financial markets.”

“The Board would like to thank Jonathan Royce for his efforts and dedication during his tenure with us. Despite the challenges we faced, he has worked strenuously to lead Bio-Works, and we appreciate his contributions. We are confident that Lone Carlbom has the experience and skills required to lead Bio-Works towards a stronger and more successful future”, Ehrenheim concluded.
———————-
Lone Carlbom brings over 25 years of experience in leadership roles within the Life Sciences and Biotech industries, with expertise in product management, technical support, and sales. Previously, she held the position of Head of Chromatography Resines and BioProcess Equipment at GE Healthcare Life Sciences (now Cytiva). Additionally, she has served as a consultant in change management and organizational development.

About Bio-Works
Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works’ next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North (“BIOWKS”), and FNCA Sweden AB is appointed Certified Adviser. For more information, visit www.bio-works.com.